Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ562MR)

This product GTTS-WQ562MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Gastric Cancer, Breast Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, 4D5-8(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ562MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12879MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ3680MR IVTScrip™ mRNA-Anti-F11, BAY 1213790(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 1213790
GTTS-WQ9314MR IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IMP-321
GTTS-WQ12813MR IVTScrip™ mRNA-Anti-MASP2, OMS721(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA OMS721
GTTS-WQ12313MR IVTScrip™ mRNA-Anti-CSF2, MT203(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MT203
GTTS-WQ7723MR IVTScrip™ mRNA-Anti-GLP1R, GLP-1Fc(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GLP-1Fc
GTTS-WQ15169MR IVTScrip™ mRNA-Anti-CD6, T1h(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA T1h
GTTS-WQ10413MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY2439821
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW